{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "medicine:vascular:pharmacology:anticoagulation:ac-001",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T05:06:00.000Z",
    "contributors": [
      "copilot"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "board_yield": "HIGH",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology/anticoagulation",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "foundational"
  },
  "content": {
    "title": "Anticoagulation in Vascular Surgery",
    "definition": "Pharmacological inhibition of the coagulation cascade to prevent and treat thrombosis. Essential for management of venous thromboembolism, atrial fibrillation, prosthetic valves, and perioperative anticoagulation in vascular procedures.",
    "key_concepts": [
      {
        "term": "Unfractionated Heparin (UFH)",
        "description": "Activates antithrombin III \u2192 inhibits thrombin (IIa) and factor Xa; IV administration; monitored by aPTT (target 1.5-2.5x control); rapidly reversible with protamine. Standard for intraoperative anticoagulation"
      },
      {
        "term": "Low Molecular Weight Heparin (LMWH)",
        "description": "Enoxaparin, dalteparin; more predictable pharmacokinetics than UFH; SC administration; anti-Xa monitoring in renal failure/obesity; partial reversal with protamine"
      },
      {
        "term": "Warfarin",
        "description": "Vitamin K antagonist; inhibits factors II, VII, IX, X (vitamin K-dependent); monitored by INR; slow onset (3-5 days for effect); target INR 2-3 for most indications"
      },
      {
        "term": "Direct Oral Anticoagulants (DOACs)",
        "description": "Direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitor (dabigatran); fixed dosing; no routine monitoring; limited reversal options"
      },
      {
        "term": "DOAC Advantages",
        "description": "Fixed dosing, no monitoring, fewer drug/food interactions, rapid onset/offset, lower intracranial bleeding vs warfarin; preferred for VTE and non-valvular AFib"
      },
      {
        "term": "DOAC Reversal",
        "description": "Dabigatran: idarucizumab (Praxbind); Factor Xa inhibitors: andexanet alfa (Andexxa); 4-factor PCC (off-label); hemodialysis for dabigatran"
      },
      {
        "term": "Intraoperative Anticoagulation",
        "description": "Heparin 80-100 units/kg IV for vascular clamping; ACT (activated clotting time) target 250-300 seconds; additional doses for prolonged cases; reversal with protamine 1mg per 100 units heparin"
      },
      {
        "term": "Bridging Anticoagulation",
        "description": "Perioperative management for patients on long-term anticoagulation; LMWH or UFH bridge for high-risk patients; low-risk patients may not need bridging (BRIDGE trial)"
      },
      {
        "term": "VTE Treatment Duration",
        "description": "Provoked VTE: 3 months; Unprovoked VTE: 3-6 months minimum, consider extended if low bleeding risk; Cancer-associated VTE: extended duration"
      },
      {
        "term": "Bleeding Risk Assessment",
        "description": "HAS-BLED score for atrial fibrillation; balance bleeding risk against thrombotic benefit; major bleeding on anticoagulation is significant morbidity"
      }
    ],
    "clinical_features": {
      "snomed_codes": [
        "372756006",
        "387458008"
      ],
      "icd_10_codes": [
        "Z79.01",
        "Z79.02"
      ],
      "indications": [
        "DVT",
        "PE",
        "Atrial fibrillation",
        "Prosthetic heart valve",
        "Post-vascular procedure",
        "Acute coronary syndrome"
      ]
    },
    "relationships": {
      "skos:broader": [
        "medicine:pharmacology:cardiovascular"
      ],
      "skos:related": [
        "medicine:vascular:pathology:dvt",
        "medicine:vascular:pharmacology:antiplatelet:ap-001",
        "medicine:hematology:coagulation"
      ],
      "skos:narrower": []
    },
    "statement": "Anticoagulation in Vascular Surgery is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology Anticoagulation that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Anticoagulation in Vascular Surgery helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Anticoagulation in Vascular Surgery include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Anticoagulation in Vascular Surgery."
    }
  },
  "pedagogical": {
    "learning_objectives": [
      "Know anticoagulant classes and mechanisms",
      "Understand intraoperative heparin dosing and reversal",
      "Apply VTE treatment duration guidelines",
      "Balance bleeding risk against thrombotic benefit"
    ],
    "clinical_pearls": [
      "Heparin 80-100 units/kg for vascular clamping; target ACT 250-300",
      "Protamine 1mg per 100 units heparin for reversal",
      "DOACs preferred over warfarin for most VTE and non-valvular AFib",
      "Provoked VTE = 3 months; unprovoked = consider extended therapy",
      "Bridging may not be needed for low-risk patients (BRIDGE trial)",
      "Idarucizumab reverses dabigatran; andexanet alfa for Xa inhibitors"
    ],
    "common_mistakes": [
      "Not accounting for renal function with LMWH and DOACs",
      "Over-reversing heparin with protamine (causes hypotension, bradycardia)",
      "Bridging low-risk patients (increases bleeding without benefit)",
      "Using DOACs with mechanical heart valves (contraindicated)"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Anticoagulation in Vascular Surgery. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}